UC Irvine UC Irvine Previously Published Works

Title

Hepatitis C virus and death risk in hemodialysis patients.

Permalink

https://escholarship.org/uc/item/0mx245ms

Journal

AMERICAN JOURNAL OF KIDNEY DISEASES, 47(4)

ISSN

0272-6386

Authors

Kalantar-Zadeh, K McAllister, CJ Miller, LG <u>et al.</u>

Publication Date

2006

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Peer reviewed


73

A37

HEPATITIS C VIRUS AND DEATH RISK IN HEMODIALYSIS PATIENTS. <u>Kamyar Kalantar-Zadeh¹</u> Charles J McAllister², Loren G Miller³, Eric S Daar⁴, David W Gjertson⁵, Joel D Kopple¹, Sander Greenland⁵, and Ryan D Kilpatrick¹. ¹Divisions of Nephrology, ³Infectious and ⁴HIV Disease; LA BioMed at Harbor-UCLA, Torrance, CA; ⁵UCLA School of Public Health, and ²DaVita, Inc, El Segundo, CA

Hepatitis C virus (HCV) infection is common in maintenance hemodialysis (MHD) patients. We hypothesized that HCV infection is associated with an increased all-cause and cause specific death risk in MHD patients. We analyzed survival in a 3-year (7/2001-6/2004) national cohort of

82,958 MHD patients, 13,664 of whom underwent HCV enzyme immunoassay (EIA) testing. The HCV EIA was reported positive in 1,590 MHD patients (12%). In fully adjusted survival models, HCV infection associated death hazard was 1.25 (95% confidence interval: 1.12-1.39). This death risk was more prominent among incident (vintage <6 mos) than prevalent MHD patients. Subgroup analyses showed tendency towards death risk across almost all



clinical, demographic and laboratory subgroups of MHD patients (Figure). Hence, HCV infection, as diagnosed by EIA, is associated with significantly higher mortality risk. More diligent HCV detection and treatment may improve survival in MHD patients.